吸入糖皮质激素联合噻托溴铵治疗哮喘—慢性阻塞性肺病重叠综合征120例(1)
【摘 要】目的：分析吸入糖皮质激素联合噻托溴铵治疗哮喘-慢性阻塞性肺病重叠综合征的治疗效果。方法：随机抽取我院呼吸内科接收并治疗的哮喘-慢性阻塞性肺病重叠综合征患者共240例，设为研究组和常规组各120例，研究组采用吸入糖皮质激素联合噻托溴铵治疗。常规组采用噻托溴铵治疗，比较两组临床效果。结果：治疗后，研究组ACT哮喘症状评分为(24.85±3.43)分，CAT慢阻肺症状评分(16.33±1.01)分，治疗效果均明显优于常规组(p<0.05)。结论：吸入糖皮质激素联合噻托溴铵治疗哮喘-慢性阻塞性肺病重叠综合征能明显改善患者临床症状，较单纯使用噻托溴铵效果显著，可临床推广应用。
【关键词】吸入糖皮质激素；噻托溴铵；哮喘-慢性阻塞性肺病重叠综合征
Inhaled corticosteroids combined with tiotropium bromide in the treatment of 120 cases of asthma chronic obstructive pulmonary disease overlap syndrome
, 百拇医药
CAO Zhongzhi
(Nantong University Affiliated Nanjing Jiangbei People's Hospital，Nanjing 210048 China)
【Abstract】Purpose：To analyze the therapeutic effect of inhaled glucocorticoid combined with thiotromonium in the treatment of asthmic-chronic obstructive pulmonary disease overlapping syndrome. Methods：A total of 240 cases of asthmic-chronic obstructive pulmonary disease overlapping syndrome received and treated by our department of respiratory medicine were randomly selected. The study group was set up as 120 cases each in the normal group and the group was treated with inhaled glucocorticoid combined with tiatropium. The conventional group was treated with tiotromonium bromide， and the clinical results of the two groups were compared. Results：After treatment， the team's ACT asthma symptoms score was(24.85 ± 3.43) points， and CAT slow obstructive pulmonary symptoms score(16.33 ± 1.01) points， and the treatment effect was significantly better than that of the normal group (p<0.05). Conclusion：Inhalation of glucocorticoid combined with thiotromonium for the treatment of asthmic-chronic obstructive pulmonary disease overlapping syndrome can significantly improve the clinical symptoms of patients， and is more effective than the use of thiotromonium alone， and can be used clinically.
, http://www.100md.com
【Keywords】Inhalation of glucocorticoids； Thiotromonium； Asthma and chronic obstructive pulmonary disease (copd) overlap syndrome.
哮喘-慢性阻塞性肺病重叠综合征(Asthma and chronic obstructive pulmonary disease (copd) overlap syndrome，ACOS)是指持续性气流受限，同时具有哮喘和慢性阻塞性肺疾病相关特征的疾病[1]，随着年龄增长发病率呈上升趋势[2-4]。患者常伴有咳嗽、咳痰、气喘、呼吸困难等症状，严重影响患者的生活质量[5]。寻求有效的治疗方法，是本文研究的目的。本研究选择我院240例哮喘-慢性阻塞性肺病重叠综合征患者为研究对象，分析吸入糖皮质激素联合噻托溴铵治疗哮喘-慢性阻塞性肺病重叠综合征的效果。以下是具体的试验报告。
1 研究对象与方法
, http://www.100md.com
1.1研究对象
选取2015年11月到2017年11月期间我院呼吸内科接收并治疗的哮喘-慢性阻塞性肺病重叠综合征患者中抽取的240例。纳入标准：(1)符合哮喘-慢性阻塞性肺病重叠综合征的临床判定标准者；(2)不典型患者行胸部X线、胸部CT檢查者；(3)患者治疗前1个月未接受全身激素治疗者；(4)签署知情同意书者。排除标准：(1)不符合纳入标准者；(2)合并患有高血压、严重内科疾病者；(3)治疗依从性差者；(4)不符合糖皮质激素、噻托溴铵治疗者；(5)合并精神类疾病者；(6)哺乳期、孕妇。按照随机数字表分法分为研究组和常规组，研究组120例，采用吸入糖皮质激素联合噻托溴铵治疗，其中，男60名，女60名，年龄49到81岁，平均(60.14±0.23)岁。常规组120例采用噻托溴铵治疗，其中，男59名，女61名，年龄50到83岁，平均(60.79±0.55)岁。应用生物统计学分析本研究对象的一般资料显示，P值大于0.05，可进行对比。, 百拇医药(曹忠志)
【关键词】吸入糖皮质激素；噻托溴铵；哮喘-慢性阻塞性肺病重叠综合征
Inhaled corticosteroids combined with tiotropium bromide in the treatment of 120 cases of asthma chronic obstructive pulmonary disease overlap syndrome
, 百拇医药
CAO Zhongzhi
(Nantong University Affiliated Nanjing Jiangbei People's Hospital，Nanjing 210048 China)
【Abstract】Purpose：To analyze the therapeutic effect of inhaled glucocorticoid combined with thiotromonium in the treatment of asthmic-chronic obstructive pulmonary disease overlapping syndrome. Methods：A total of 240 cases of asthmic-chronic obstructive pulmonary disease overlapping syndrome received and treated by our department of respiratory medicine were randomly selected. The study group was set up as 120 cases each in the normal group and the group was treated with inhaled glucocorticoid combined with tiatropium. The conventional group was treated with tiotromonium bromide， and the clinical results of the two groups were compared. Results：After treatment， the team's ACT asthma symptoms score was(24.85 ± 3.43) points， and CAT slow obstructive pulmonary symptoms score(16.33 ± 1.01) points， and the treatment effect was significantly better than that of the normal group (p<0.05). Conclusion：Inhalation of glucocorticoid combined with thiotromonium for the treatment of asthmic-chronic obstructive pulmonary disease overlapping syndrome can significantly improve the clinical symptoms of patients， and is more effective than the use of thiotromonium alone， and can be used clinically.
, http://www.100md.com
【Keywords】Inhalation of glucocorticoids； Thiotromonium； Asthma and chronic obstructive pulmonary disease (copd) overlap syndrome.
哮喘-慢性阻塞性肺病重叠综合征(Asthma and chronic obstructive pulmonary disease (copd) overlap syndrome，ACOS)是指持续性气流受限，同时具有哮喘和慢性阻塞性肺疾病相关特征的疾病[1]，随着年龄增长发病率呈上升趋势[2-4]。患者常伴有咳嗽、咳痰、气喘、呼吸困难等症状，严重影响患者的生活质量[5]。寻求有效的治疗方法，是本文研究的目的。本研究选择我院240例哮喘-慢性阻塞性肺病重叠综合征患者为研究对象，分析吸入糖皮质激素联合噻托溴铵治疗哮喘-慢性阻塞性肺病重叠综合征的效果。以下是具体的试验报告。
1 研究对象与方法
, http://www.100md.com
1.1研究对象
选取2015年11月到2017年11月期间我院呼吸内科接收并治疗的哮喘-慢性阻塞性肺病重叠综合征患者中抽取的240例。纳入标准：(1)符合哮喘-慢性阻塞性肺病重叠综合征的临床判定标准者；(2)不典型患者行胸部X线、胸部CT檢查者；(3)患者治疗前1个月未接受全身激素治疗者；(4)签署知情同意书者。排除标准：(1)不符合纳入标准者；(2)合并患有高血压、严重内科疾病者；(3)治疗依从性差者；(4)不符合糖皮质激素、噻托溴铵治疗者；(5)合并精神类疾病者；(6)哺乳期、孕妇。按照随机数字表分法分为研究组和常规组，研究组120例，采用吸入糖皮质激素联合噻托溴铵治疗，其中，男60名，女60名，年龄49到81岁，平均(60.14±0.23)岁。常规组120例采用噻托溴铵治疗，其中，男59名，女61名，年龄50到83岁，平均(60.79±0.55)岁。应用生物统计学分析本研究对象的一般资料显示，P值大于0.05，可进行对比。, 百拇医药(曹忠志)
参见：首页 > 医疗版 > 疾病专题 > 呼吸内科 > 气管、支气管疾病 > 阻塞性肺气肿